Revolution Medicines (MIL:1RVMD) Other Current Receivables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1RVMD Revolution Medicines Inc MIL:1RVMD
9 GF Score
Price €165.80
GF Value €0.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Revolution Medicines Other Current Receivables?

Revolution Medicines MIL:1RVMD +2.16% 9 Other Current Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates MIL:1RVMD with a GF Score™ of 9/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Revolution Medicines's Other Current Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Revolution Medicines Other Current Receivables Related Terms

Revolution Medicines Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Revolution Medicines's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Medicines Other Current Receivables Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Revolution Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MIL:1RVMD
9GF Score
Revolution Medicines Inc MIL:1RVMD
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revolution Medicines Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.00 Mil mean?
Revolution Medicines (MIL:1RVMD) has a Other Current Receivables of €0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Revolution Medicines and its competitors.
Is Revolution Medicines' Other Current Receivables too high?
Revolution Medicines' current Other Current Receivables is €0.00 Mil. Overall, Revolution Medicines has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' Other Current Receivables compare to ALNY and ONC?
Revolution Medicines' Other Current Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current Other Current Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (MIL:1RVMD) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €165.80 — trading 40339% above its estimated fair value. The current Other Current Receivables is €0.00 Mil. Revolution Medicines' overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Revolution Medicines (MIL:1RVMD), the current Other Current Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revolution Medicines (MIL:1RVMD) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €165.80 is trading 40339% above its estimated GF Value™ of €0.41. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for MIL:1RVMD:

  • Other Current Receivables: €0.00 Mil
  • GF Value™: €0.41 vs. price of €165.80 (40339% above fair value)
  • GF Score™: 9/100 with 4 warning signs

No single metric tells the full story. See the MIL:1RVMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revolution Medicines Business Description

Other Exchanges RVMD:USA42Z:Germany
Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
9GF Score

Get the complete analysis for MIL:1RVMD

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€165.80
Price
€0.41
GF Value